News | September 05, 2025
FDA completes inspection at Biocon Biologics' facility in Bengaluru
The U.S. FDA issued a Form 483 with five observations
The U.S. FDA issued a Form 483 with five observations
At the end of the current inspection, a 'Form 483' was issued with 5 observations which are procedural in nature and no data integrity issues were reported
The US generic market is crucial for Indian pharma, contributing about 35% to its total revenue, around US$ 10.7 billion
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
The therapy delivers the full-length ABCA4 protein and has the potential to benefit all patients with ABCA4 mutations
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
The campaign celebrates radiant, healthy skin that shines naturally, empowering women to step forward with confidence in every walk of life.
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients
The company received one observation in the Form-483
The company received 1 (One) observation in the Form-483
Subscribe To Our Newsletter & Stay Updated
